熱門資訊> 正文
雷蒙德·詹姆斯（Raymond James）以FDA不可靠的批准为由，将ARS推高至强势购买
2024-08-14 00:26
- Raymond James has raised ARS Pharmaceuticals (NASDAQ:SPRY) to strong buy, citing the recent approval of its epinephrine nasal spray, neffy.
- Noting that FDA approval for the product came earlier than expected, Raymond James said its upgrade was driven by multiple tailwinds for the product, including a label that looks roughly the same as epinephrine autoinjectors and a 30-month shelf life.
- The investment bank sees neffy appealing to both autoinjector users and patients who were unwilling to carry the drug in the past.
- It also noted that neffy has received considerable media exposure, which has raised awareness of the product ahead of the company’s direct-to-consumer campaign.
- Raymond James set a price target of $22 for the stock.
- Aquestive Therapeutics (AQST) is also developing a non-injected epinephrine product called Anaphylm, which is taken by mouth.
More on ARS Pharmaceuticals
- ARS Pharmaceuticals, Inc. (SPRY) ARS Pharmaceuticals neffy (epinephrine nasal spray) FDA Approval Conference Call Transcript
- ARS Pharmaceuticals neffy (epinephrine nasal spray) FDA Approval Conference Call
- ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles
- ARS stock jumps 13% on FDA approval of epinephrine nasal spray (update)
- ARS Pharmaceuticals nasal spray for anaphylaxis endorsed in EU
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
